“Endpoint Selection in Rare Disease Trials: Composite Measures and the Loss of Interpretability”. Translational Medicine & Therapeutics Journal, vol. 5, no. 2, Feb. 2026, pp. 10-18, https://doi.org/10.5281/zenodo.22649538.